Bristol-Myers Squibb demonstrated robust Q3 performance, with a 17% year-over-year revenue increase driven by strong demand across its growth portfolio, prompting an upward revision of the top-line guidance.

• Growth portfolio sales surged 17% year-over-year, supported by strong performance from key products including Reblozyl, Camzyos, and Breyanzi.
• Clinically significant progress with Iberdomide in multiple myeloma showed improved MRD negativity rates, with ongoing studies expected to yield further data by 2026.
• Successful launches of new products Cobenfy and Qvantig, with Cobenfy continuing to receive positive market feedback contributing to solid early growth.
• Breakthrough therapy designation for Iza-bren highlights the pipeline's potential in addressing unmet medical needs, particularly in oncology and neurology.
• Acquisition of Orbital Therapeutics enhances the cell therapy division and introduces novel RNA technology that could innovate treatment approaches in autoimmune diseases.